3401 N. Central Avenue Chicago, IL 60634




What is this study investigating?

The overall goal of the study is to evaluate the safety and effectiveness of the investigational drug plus an oral antidepressant, compared to placebo plus and oral antidepressant in patients with Major Depressive Disorder.

What medications are being used? Qualified candidates will be started on one of the following FDA-approved antidepressant medications: Zoloft® (Sertraline), Celexa® (Citalopram), Lexapro® (Escitalopram), Pristiq®(Desvenlafaxine), or Cymbalta® (Duloxetine). Which medication chosen is based off of our psychiatrist’s recommendation. SAGE-217 (Zuranolone) is an oral investigational product that is dosed for 14-days in the beginning of your treatment with a traditional antidepressant.

Overview: This is a 6-week long clinical trial that entails 2-3 in-office visits per week.

You May Qualify If:
–        You are 18 to 65 years of age
–        You are NOT currently on an antidepressant medication
–        You are experiencing symptoms of depression
–        Please Note: If you are an individual of child-bearing potential, you are required to be one (1) of the following:

  • On a highly effective form of birth control (i.e. oral pill, patch, IUD, implant, etc.)
    –  Abstinence, condoms, and spermicide are NOT considered highly effective forms of birth control. No exceptions.
  • Surgically sterilized (i.e. tubal ligation or hysterectomy)
  • Have a vasectomized partner
  • Engage exclusively in same-sex relationships

Qualified candidates may be compensated $75 per visit. Free transportation assistance may be provided to those who enroll.

Contact Us